SCHEMBL156189

SCHEMBL156189

N[C@@H](Cc1ccc(-c2ccc(C[C@H](N)C(=O)O)cc2)cc1)C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.74
PTGS1 P23219 3/20 0.73
ALPI P09923 1/20 0.73
PKM P14618 1/20 0.73
XIAP P98170 1/20 0.73
HIF1A Q16665 4/20 0.61
ALOX15 P16050 3/20 0.61
KDM4E B2RXH2 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
HSD17B10 Q99714 2/20 0.61
USP2 O75604 1/20 0.61
EGFR P00533 1/20 0.61
LCK P06239 1/20 0.61
FYN P06241 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
HTR2A P28223 1/20 0.61
PTGS2 P35354 1/20 0.61
RECQL P46063 1/20 0.61
TPH1 P17752 2/20 0.61
GRB2 P62993 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837014 1.00 SLC7A5 (0.74) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93494 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL414363 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL180272 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93495 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL1796036 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.93 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31369911 0.92 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31369642 0.92 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL3695982 0.92 SLC7A5 (0.75) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 869 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240247034-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2024-07-25 US claimed
EP-3169403-B9 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-07-03 EP claimed
US-20240083944-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2024-03-14 US claimed
US-11904020-B2 Bicyclic peptide ligands specific for TREM2 BICYCLETX LIMITED (GB) 2024-02-20 US claimed
EP-3169403-B1 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-02-14 EP claimed
EP-4308586-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 BicycleTX Limited (GB) 2024-01-24 EP claimed
EP-4274839-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS BicycleTx Limited (GB) 2023-11-15 EP claimed
EP-4274841-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS BicycleTx Limited (GB) 2023-11-15 EP claimed
CN-117062826-A Antiinfective bicyclic peptide ligands 拜斯科技术开发有限公司 2023-11-14 CN claimed
CN-117043176-A Antiinfective bicyclic peptide ligands 拜斯科技术开发有限公司 2023-11-10 CN claimed
US-6734166-B1 ADMINISTERING A PYY RECEPTOR AGONIST NORTH CAROLINA STATE UNIVERSITY 2004-05-11 US claimed
WO-2003070769-A2 ORGANIC COMPOUNDS HAVING ANTI-ANGIOGENIC ACTIVITY NOVARTIS AG (CH) 2003-08-28 WO claimed
WO-2003064458-A2 NOVEL PEPTIDE DERIVATIVES, PREPARATION AND THERAPEUTIC AND COSMETIC APPLICATION THEREOF INSTITUT EUROPEEN DE BIOLOGIE CELLULAIRE (FR) 2003-08-07 WO claimed
EP-0950046-B1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS NAEJA PHARMACEUTICAL INC (CA) 2002-04-10 EP claimed
US-6232305-B1 ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS NAEJA PHARMACEUTICAL INC. (CA) 2001-05-15 US claimed
EP-1025127-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES Wapharm AB (SE) 2000-08-09 EP claimed
EP-0950046-A1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS SYNPHAR LABORATORIES INC. (CA) 1999-10-20 EP claimed
US-5959123-A REACATING SUBSTITUTED AMINO ACID WITH 3-AMINO-4-SUBSTITUTED-AZETIDINE-2-ONE COMPOUND TO FORM 3, 4-DISUBSTITUTED-AZETIDINE-2-ONE COMPOUND; USEFUL FOR TREATING MUSCULAR DYSTROPHY, ARTHRITIS, VIRAL AND PARASITIC INFECTIONS SYNPHAR LABORATORIES, INC. (CA) 1999-09-28 US claimed
WO-1998037097-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES WAPHARM AB (SE) 1998-08-27 WO claimed
WO-1998012176-A1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS SYNPHAR LABORATORIES INC. (US) 1998-03-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11904020-B2 Bicyclic peptide ligands specific for TREM2 APP, TIMCC, ADM2 SLC7A5 2481/4885PTGS1 3076/4885ALPI 4030/4885
US-20240083944-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS ACE2, SARS1, TMPRSS2 SLC7A5 2484/4885PTGS1 2523/4885ALPI 3760/4885
US-20240247034-A1 CYSTINE KNOT SCAFFOLD PLATFORM LRP6, LDLR, KDR SLC7A5 504/4885PTGS1 2821/4885ALPI 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.